Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL

De novo resistance and rapid recurrence often characterize responses of B-cell malignancies to ibrutinib (IBR), indicating a need to develop drug combinations that block compensatory survival signaling and give deeper, more durable responses. To identify such combinations, we previously performed a...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Blood Adv
Hlavní autoři: Jayappa, Kallesh D., Portell, Craig A., Gordon, Vicki L., Capaldo, Brian J., Bekiranov, Stefan, Axelrod, Mark J., Brett, L. Kyle, Wulfkuhle, Julia D., Gallagher, Rosa I., Petricoin, Emanuel F., Bender, Timothy P., Williams, Michael E., Weber, Michael J.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2017
Témata:
Lymphoid Neoplasia
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5637393/
https://ncbi.nlm.nih.gov/pubmed/29034364
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2016004176
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky